Regulation of Cholesterol Flashcards
Rate limiting step of cholesterol synthesis
HMG-CoA reductase catalyzes the reduction of HMG-CoA —> Mevalonate
Statins
Inhibit HMG-CoA reductase –> decrease cholesterol formation
DHCR7 gene mutatino
Codes for 7-DeHydroCholesterol Reductase (last step of cholesterol syth)
Causes Smith-Lemili-Opitz Syndrome
AR
Results in low plasma cholesterol and accumulated precursors –> toxic to brain & retina
Metabolic fates of cholesterol
- Hepatocyte membranes
- Bile acids, biliary cholesterol, cholesterol esters
- steroid hormone synthesis
- Liver/Kidney –> vitamin D synth
- Small amts oxysterols formed in LIVER –> regulators of cholesterol synth
Cholesterol esters
Formed in the LIVER
Catalyzes ACAT
FA from coenzyme A att to cholesterol –>makes cholesterol more hydrophobic –> CE secreted and stored in LIVER in lipid droplets
Bile acids
Relatively hydrophilic –> emulsify dietary fats
Helps remove excess cholesterol via excretion (enhanced by dietary fiber, allows more cholesterol to be used to make bile)
ApoB-48
Unique to chylomicron –> cholesterol transport/clearance
Core structural protein
ApoC -II
Activates lipoprotein lipase (LPL)
Exogenous pathway of lipoprotein metabolism
- Incorporation of dietary fats –> chylomicrons in intestine
- ApoC-II activates LPL
- Chylomicron remnants being stored travel to LIVER and enter ApoE ligand
VLDL
Lipids from LIVER –> peripheral tissue
ApoC-II activates LPL–> hydrolyzes TAG to glycerol & free FA
Loss of TAG converts VLDL to IDL (VLDL remnants)
In fed state
Lipids generating VLDL particles are primarily coming from the diet –> VLDL particles take lipids to adipose –> storage
In fasting state
Fatty acids from adipose travel to the LIVER to form VLDL particles –> transport FA to muscle –> make energy
LDL Particles
Function to take cholesterol to extrahepatic tissues –> bind apoB-100 (LDL receptor)
Can be taken up by macrophages –> FOAM cells
apoB-100 receptor
Recycles cell surface –> bind LDL –> cell surface
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Responsible for degradation of LDL receptor
LOF mutation –> reduced plasma LDL
GOF mutation –> increased plasma LDL
PCSK9 inhibitors
Antibodies to PCSK9
Binds PCSK9 to antibody instead of receptor –> allows receptor to continue to be recycled –> decrease plasma LDL levels